Kornimate/medical-research-clean huggingface dataset:
comparison of cardiac index and cardiac output effect during maintenance hemodialysis between acetate-free and acetate-based online hemodiafiltration

Conditions: End-stage Renal Disease

Summary: the purpose of this study is to detemine whether effect of acetate-free solution on cardiac index and cardiac output measured by saline dilution techniques compares with acetate-based solution in online-hemodiafiltration


Eligibility criteria:
inclusion criteria: * end-stage renal disease patients with age over 20 years and stable clinical status * dialytic age \> 6 months * maintenance hemodialysis with online-hemodiafiltration mode at king chulalongkorn memorial hospital * use arteriovenous fistula or arteriovenous graft as vascular access for hemodialysis * no vascular access recirculation * no liver impairment * no severe, intractable metabolic acidosis or alkalosis (hco3 \ 30) * no pre-existing severe, intractable hypocalcemia (ca \< 7.5) or clinical of hypocalcemia exclusion criteria: * on hemodialysis via tunnel catheter * vascular access recirculation * liver dysfunction * severe, intractable metabolic acidosis or alkalosis (hco3 \ 30) * pre-existing severe, intractable hypocalcemia (ca \< 7.5) or clinical of hypocalcemia * acute or recent myocardial ischemia or congestive heart failure (within 1 months) * threatening arrhythmia (vt, vf, sustained svt, af with rapid ventricular response) * patients affected by acute or chronic infections, malignant tumor
a phase ib, open-label, multi-center dose-finding study of oral panobinostat (lbh589) in combination with ara-c and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: the study will determine the maximal tolerated dose (mtd) of panobinostat administered in combination with a fixed combination of cytarabine (ara-c) and mitoxantrone in adult patients with relapsed or refractory acute myeloid leukemia (aml).


Eligibility criteria:
inclusion criteria: * patients with cytopathologically confirmed diagnosis of aml according to who criteria, excluding acute promyelocytic leukemia. * first relapsed aml * primary refractory aml defined as failure to respond to initial induction chemotherapy (no cr) or recurrence within 6 months of initial cr. * age more than 18 years * ecog performance status \< 2 exclusion criteria: * prior treatment with deacetylase inhibitor * concurrent therapy with any other investigational agent * patients who have received cumulative doses (or its equivalent to other anthracyclines) of more than 360 mg/m2 of doxorubicin will be excluded from the study. * clinical symptoms suggesting cns leukemia * lvef below 45% other protocol-defined inclusion/exclusion criteria may apply

Keywords: acute myeloid leukemia aml relapsed acute myeloid leukemia refractory acute myeloid leukemia
cost effectiveness of prolotherapy injections prior to total knee arthroplasty

Conditions: Knee Osteoarthritis

Summary: this study compared the cost effectiveness of two-stage algorithm (prolotherapy injections (prt) combined with rehabilitation protocol (rp) prior to total knee arthroplasty (tka)) and one-stage algorithm (tka) in the management of advanced stage knee osteoarthritis.

the aim of the present study was to compare the cost effectiveness of two-stage algorithm (prolotherapy injections (prt) combined with rehabilitation protocol (rp) prior to total knee arthroplasty (tka)) and one-stage algorithm (tka) in the management of advanced stage knee osteoarthritis. a total of 197 patients who had chronic knee osteoarthritis were included in the present study. the patients were divided into two groups as two-stage algorithm (prt combined with rp prior to tka), (group a, n=98) and one-stage (tka),(group b, n=99). clinical effectiveness was evaluated via visual analog scale (vas), the western ontario and mcmaster universities arthritis index (womac) at baseline and 3-, 6-, 12-, and 18-month follow-ups. utility scores of the groups were obtained by extracting and converting womac scores to health utilities index mark 3 scores. cost-utility per quality-adjusted life years (qaly) and incremental cost-effectiveness ratios (icers) of each group were calculated.

Eligibility criteria:
inclusion criteria: * iii and iv levels of knee osteoarthritis according to kellgren-lawrence * had at least six months of symptoms resistant to at least three months of conservative methods (lifestyle modification, weight reduction, regular exercise, physiotherapy, non-steroidal anti-inflammatory drugs, intraarticular injection methods) - exclusion criteria: * with rheumatic diseases, immune diseases or other systemic inflammatory diseases * with active infection, osteomyelitis or history of chronic infection around knee joint * had undergone previous operation on knee * had bleeding tendency (hereditary or acquired) * pregnant patients

Keywords: arthroplasty prolotherapy osteoarthritis
dna biomarkers in samples from patients with osteosarcoma and healthy volunteers

Conditions: Sarcoma

Summary: rationale: studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying dna biomarkers in samples from patients with osteosarcoma and healthy volunteers.

objectives: * to determine whether common copy-number alterations (cnas) at chr7p14.1 arise de novo in osteosarcoma (os) tumor dna or whether they represent progression of constitutional copy-number variations (cnvs). * to determine the association between constitutional cnvs at chr7p14.1 and susceptibility to os. * to determine how cnvs translate into cnas in tumor dna samples from patients with os. outline: rna and dna samples from banked blood and paired tumor tissue, plus samples from healthy controls, are analyzed for common copy-number alterations and constitutional copy-number variations (cnvs) at chr7p14.1 by microarray, q-pcr, rt-pcr, and fish. osteosarcoma predisposing cnvs results are then compared among cases versus healthy controls. clinical information associated with each osteosarcoma sample (i.e., gender, age of diagnosis, tumor site, tumor type and grade, presence of metastases at time of diagnosis, response to chemotherapy, event-free survival, and overall survival) is also collected, if available. projected accrual: a total of 243 samples from patients with osteosarcoma and 80 samples from healthy controls will be accrued to this study.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * diagnosis of osteosarcoma (os) and meets 1 of the following criteria: * original 153 os samples, including paired germline and tumor dna * additional samples from 90 patients with os: * blood samples * germline dna * paired tumor biopsy tissue (not from resection) obtained before systemic chemotherapy * healthy controls, age- and gender-matched patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: osteosarcoma
study to assess the efficacy and safety of endolex forte versus diosmin and hesperidin in reducing venous insufficiency

Conditions: Chronic Venous Insufficiency

Summary: the trial is designed as a randomized, multicenter, open label, comparative, 6 months, clinical study.

a randomized, multicentered, open label, comparative study to assess the efficacy and safety of endolex forte® versus a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) in reducing the symptomatology of patients diagnosed with chronic venous insufficiency which is rated between functional classes ceap 1-4, during a period of 6 months.

Eligibility criteria:
inclusion criteria: * patients, male or females aged 18 to 75 years old * bmi≤40 * presence of chronic venous insufficiency which is rated between functional classes ceap 1-4 * patients diagnosed with superficial vein thrombophlebitis and have skin reaction by redness, swelling, fever and pain symptoms.or patients presenting a painful venous symptomatology in the lower limbs for at least 30 days. * willing and able to give written informed consent prior to participation in the trial * patients expected to be compliant with the study treatment exclusion criteria: * known allergy to the product's ingredients * pregnancy or breastfeeding * patient is involved in any other clinical trial * deep vein thrombosis * stasis dermatitis * the patient is taking non-steroids anti-inflammatory drugs include oral , topical creams or patch form) * open ulcers or lower extremity amputation * patient treated by venotonic treatments or vascular protectants or assimilated dietary supplements or homeopathic treatments or diuretics within 15 days prior inclusion * patient presenting permanent oedema, * patient with a history of lower limbs trauma responsible for sequel pains * nyha iii and iv heart failure * renal failure * untreated or uncontrolled arterial hypertension * hepatic failure * history of a known liver disease such as hepatitis a, hepatitis b, or c. * malignant neoplasms, from any etiology, or who are receiving any type of anticancer treatment, unless when properly treated and with no evidence of recurrence during the last five years * previous history of alcoholism, drug abuse, psychological or emotional problems in the last 5 years that can invalidate the informed consent form or restrain participant's ability to comply with the requirements of the protocol. * immobility.

Keywords: venous insufficiency
clinical trial evaluating metronomic chemotherapy in patients with metastatic osteosarcoma

Conditions: Osteosarcoma

Summary: preclinical models show that a daily antiangiogenic regimen at low-dose may be effective against chemotherapy-resistant tumors. the aim of this study is to evaluate the efficacy of maintenance therapy with continuous oral cyclophosphamide and methotrexate in patients with high grade, operable, metastatic osteosarcoma (ost) of the extremities. the primary end point is event-free survival (efs) from randomization

the study design includes backbone of 10 weeks of preoperative therapy using map (high-dose methotrexate, cisplatin, doxorubicin and dexrazoxane). metastatic patients were randomized to high-dose chemotherapy for 31 weeks (arm 1) or concomitant metronomic therapy (mtx plus cyclophosphamide) such as 31 weeks of high-dose chemotherapy, followed by 73 weeks of metronomic therapy after completion of high-dose chemotherapy, totaling 104 weeks of metronomic therapy (arm 2).

Eligibility criteria:
inclusion criteria: * a newly diagnosed patient, previously untreated, with a high degree of malignancy, confirmed by biopsy. participant with ost as a neoplasm are also eligible * participant with staging imaging studies performed less than four weeks. otherwise, it should be re-staged * if pre-chemotherapy amputation is necessary, the participant will enter the study being excluded from the evaluation of tumor necrosis grade according to huvos, but eligible for survival analysis * participant aged ≥ 16 years should have a karnofsky performance score\> 50 or who / ecog ≥ 2 and patients \ 50. participant with a performance score impaired by the presence of a pathological fracture are eligible * patients with normal organic function * sexually active participant should agree to use contraceptive methods throughout the treatment * female participant should have a negative pregnancy test exclusion criteria: * if the participant or their legal guardian refuses to sign the informed consent form / consent term it will not be included in the study.

Keywords: osteosarcoma metastatic metronomic therapy
effects of dietary fructose reduction in children with hepatic steatosis

Conditions: Non-alcoholic Fatty-liver Disease

Summary: primary objectives: 1. to determine whether a 4 week reduction in dietary fructose intake improves hepatic steatosis in overweight children who have a baseline high fructose consumption and hepatic steatosis. 2. to determine if a 4 week reduction of dietary fructose improves fasting plasma triglycerides, free fatty acids, very low-density lipoprotein, insulin and glucose as well as post-prandial levels in response to a high fructose meal. 3. to determine if a 4 week reduction of dietary fructose improves markers of oxidative stress. study design: a blinded randomized study comparing glucose beverages to isocaloric fructose beverages administered over 4 weeks.

planned sample size: phase 1) 96 subjects phase 2) 40 subjects patient population: overweight hispanic children with non-alcoholic fatty-liver disease age 11 to 18 years who are stable and not taking any chronic medication with no recent acute illnesses. definitions: * bmi \>95th %tile for age and gender * self-identified as hispanic/latino * baseline hepatic fat fraction \> 10% (have nonalcoholic fatty liver disease) * sweetened beverage intake of at least 24 ounces/day

Eligibility criteria:
inclusion criteria: * bmi \> 85th %tile * self identified as hispanic * age 11-18 years * baseline hepatic fat fraction \>8% * self reported sugar beverage intake of at least 24 oz (equivalent to 3 sugar sweetened drinks per day). exclusion criteria: * currently attempting weight gain or weight loss * cirrhosis visible on baseline mri * renal insufficiency found on screening labs (creatinine \> 2) * recent acute illness within past 4 weeks (defined by fever \> 100.4ºf) * pregnancy * chronic illness requiring medication including diabetes * fasting glucose \>120 on screening labs

Keywords: nash non-alcoholic fatty-liver disease hispanic overweight
effect of group pilates and yoga exercise classes for chronic cervical pain

Conditions: Cervical Pain

Summary: exercise has been found to be effective in alleviating back and neck pain. two exercise methods which are available in the community in a group format are yoga and pilates. while there is some research on the efficacy of these exercise methods for low back pain, there is no definitive research on the use of yoga or pilates group exercise for individuals with chronic cervical pain.this study investigated the effect of group yoga and pilates exercise compared to a wait-listed control group on impairments and function related to neck pain for individuals with chronic cervical pain.

individuals reporting chronic mild to moderate neck pain for more than 3 months were assigned to a pilates, yoga or wait-listed control group. the exercise group consisted of 12 one hour small group sessions instructed by experienced physical therapists with additional yoga or pilates training. participants were evaluated at baseline, 6 weeks, and 12 weeks. exercise participants also completed a follow up 6 weeks after completion.

Eligibility criteria:
inclusion criteria: * able to attend at 12 exercise class sessions (once a week for an hour) * stable moderate to severe neck pain (3/10- 8/10) present for \> 3 months * able to get up and down off the floor * able to ambulate in the community without an assistive device * medically stable and cleared to participate in exercise exclusion criteria: * neck pain that is easily aggravated with exercise * neurological symptoms in the arms or legs (numbness, tingling, weakness) * history of recent whiplash, spine surgery, diagnosed osteoporosis, cervical stenosis with leg symptoms * any medical conditions which does not allow active exercise * unable to make medical decisions independently or have memory problems * regularly attending pilates or yoga classes or individual sessions

Keywords: cervical pain yoga pilates exercise
il15 dendritic cell vaccine for patients with resected stage iii (a, b or c) or stage iv melanoma

Conditions: Malignant Melanoma Stage III; Malignant Melanoma Stage IV

Summary: the purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using il15 in patients with resected stage iii or stage iv melanoma

il15 is a t cell growth factor that pre-clinical data overwhelmingly suggests could have a very important role in cancer immunotherapy. a desirable property for a dendritic cell vaccine directed against cancer is the ability to efficiently prime naïve, tumor associated antigen specific t cells into potent ctls. results of studies in healthy volunteers have shown that il15 dcs are particularly efficient at priming functional melanoma specific cd8+ t cells. the use of il15 in the manufacture of the dc vaccine could result in an improved immunotherapy product.

Eligibility criteria:
inclusion criteria: * hla a201 + phenotype * biopsy-proven melanoma, stages iii (a, b and c) or stage iv.- no evidence of disease at study entry * age: 21-75 years * ecog performance status 0-1 * adequate marrow function * adequate hepatic function * adequate renal function * written informed consent exclusion criteria: * subjects with measureable non-resectable melanoma * subjects who have had chemotherapy less than 4 weeks before starting trial * subjects who received ifn-a or gm-csf less than 4 weeks before starting trial * subjects who received il2 less than 4 weeks before starting trial * subjects with a baseline ldh greater than 1.1 times the uln * subjects who are hiv positive * female subjects who are pregnant * subjects who have received corticosteroids or other immunosuppressive agents less than 4 weeks before starting trial * subjects who have asthma and/or are on treatment for asthma * subjects with angina pectoris * subjects with congestive heart failure * subjects with history of autoimmune disease including lupus, rheumatoid arthritis or thyroiditis * subjects with active infections including viral hepatitis * subjects with a history of neoplastic disease othe than melanoma within the last 5 years * history of neoplastic disease within the last 5 years except for carcinoma in situ of the cervix, superficial bladder cancer or basal/squamous cell carcinoma of the skin. * subjects who present with open wounds

Keywords: melanoma vaccine dendritic cell immune response safety efficacy
heart rate variability changes during cardiac surgery and the incidence of post-operative cardiac arrhythmias

Conditions: Cardiac Arrhythmia

Summary: the purpose of this study is to investigate non-linear heart rate variability indexes as predictors of the incidence of cardiac arrhythmias in patients undergoing cardiac surgery, including coronary artery bypass graft (cabg) and valvular surgery.


Eligibility criteria:
inclusion criteria: * all patients who will have cardiac surgery * the patient must be mentally able and willing to participate in the study * male or female patients over the age of 18 exclusion criteria: * patients with major renal, hepatic, respiratory, or cerebral dysfunction * patients with atrial fibrillation or other forms of sinus node dysfunction * patients requiring continuous artificial pacing * patients with significant congenital heart disease with or without arrhythmias * patients on intra-aortic balloon pump * patients experiencing cardiac emergencies or undergoing cardiac salvage operations
effect of different feeding method on gastrointestinal function of critical patients

Conditions: Gastrointestinal Dysfunction; Critical Illness; Nutrition Disorders

Summary: the intestine is the most vulnerable target organ in septic patients and is the first to be damaged organ in multiple organ dysfunction syndrome(mods).therefore, improving intestinal motility and mucosal barrier function is critical to the treatment of sepsis. many studies have shown that, early enteral nutrition(en) in patients with sepsis helps prevent and treat intestinal dysfunction, reducing icu mortality and length of stay in icu. however, there is little research on feeding methods. in this study the investigators will compare the outcomes of different feeding methods: continuously-pumped in 24 hours, continuouslypumped in 16 hours and intermittently-pumped through the stomach tube. the aim of this study is to investigate the effects of different feeding methods on intestinal function in septic patients.


Eligibility criteria:
inclusion criteria: 1. septic patients in department of critical care medicine, guangdong provincial hospital of chinese medicine; 2. apache-ⅱ score greater than 15 points; 3. signing the informed consent. exclusion criteria: 1. fasting patients in the clinical, such as digestive tract perforation, bleeding or postoperative patients with gastrointestinal tract; 2. allergic to enteral nutrition preparations; 3. don't want to attend the test or not with the healer.

Keywords: gastrointestinal function enteral feeding critical
evaluation of prognostic scores in patients with upper gastrointestinal bleeding and cancer

Conditions: Upper Gastrointestinal Bleeding

Summary: this is a prospective and observational study to evaluate oncologic patients that presented upper gastrointestinal bleeding with the use of some prognostic scores.

background: cancer incidence is rising worldwide, therefore complications of this condition, such as bleeding, are also expected to be more frequently seen. tumoral bleeding is usually difficult to control and the bleeding episode may represent the end stage of the malignant disease. in this context, it is relevant to study the performance of prognostic scores to prediction of clinical outcomes in patients with cancer. objective: to evaluate and compare the performance of prognostic scores to predict clinical outcomes in a group of patients with cancer of any site that has presented a recent episode of upper gastrointestinal bleeding (ugib). design: prospective and observational study. setting: cancer institute of são paulo; university of são paulo. patients: all patients with cancer referred to the endoscopy unit because of upper gastrointestinal bleeding will be included consecutively. main outcome measurements: need and amount of blood transfusions administered, need for endoscopic therapy, surgery, rebleeding, and mortality at 30 days.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of malignant neoplasm of any site, either located inside or outside of gi tract; * current evidence of bleeding in the last 48 hours, either by presenting hematemesis and/or melena, with or without hemodynamic instability. patients with hematochezia or bright red blood per rectum due to a site of bleeding in upper gi tract will also be included. exclusion criteria: * age \< 18 years-old; * suspicion or confirmation of pregnancy. * patients with no evidence of malignant neoplasm after curative surgery or oncologic therapy.

Keywords: cancer hemorrhage endoscopy gastrointestinal hemorrhage
skin aging in renal transplant patients

Conditions: Photosensitivity Disorders

Summary: determination of collagen, pigment and haemoglobin content of sun exposed and sun protected skin by siascopy. immunocompromised patients (for more than seven years) compared to immunocompetent patients. * trial in the field of transplantation / xenotransplantation

determination of collagen, pigment and haemoglobin content of sun exposed and sun protected skin by siascopy. immunocompromised patients (for more than seven years) compared to immunocompetent patients.

Eligibility criteria:
inclusion criteria: * renal transplant recipients transplanted more than seven years ago and immunocompetent probands of the same age. exclusion criteria: * refusal of informed consent, physical or psychological inability to give informed consent.